Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis.

Arch Pharm Res · 2026 · PMC13222307 · PMID 42098470

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Sensitivity analyses supported the impact of removing the MCI and prediabetic-enrolling trial, yielding a pooled estimate that favored GLP-1RAs; however, it did not reach statistical significance (8 studies; SMD − 0.20, 95% CI − 0.46 to 0.06; I 2 = 70%, Table S7).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.